Dr. A Diallo et al have conducted an interesting meta-analysis to evaluate the associations between the uric acid lowering effects of SGLT2 inhibitors and their cardiovascular benefits.

They quantified the uric acid lowering effect and observed significant associations regarding the HF-related endpoints and mortality.

Generally speaking, the study provided certain new insights in the potential mechanism of the cardiovascular benefits conferred by SGLT2 inhibitors.

However, I still have several concerns for further improvements.

1. Please give an explanation on the 1000 patient-years of follow-up as a cut-off value for "large-scale" RCTs.

2. In the final analysis, only five event-driven outcome trials were included. For those event-driven outcome trials excluded, please stated the specific reasons (for example, VERTIS-CV, CREDENCE, DAPA-CKD, DELIVER, EMPA-KiDNEY).

3. Why 3P-AMCE was not analyzed as one of the cardiovascular endpoints in the study?

4. In the method section, the authors standardize the analyses by multiplying the log statistics as described elsewhere. Please list the specific literature reference and make necessary citations.

I would like to thank the authors for their revisions. Most of my concerns have been addressed. I have one suggestion before the acceptance. As for my second concern, the authors responded that several large-scale outcome trials such as VERTIS-CV, CREDENCE, DAPA-CKD, DELIVER, EMPA-KiDNEY were not included since they did not report the data on the uric acid lowering effects. Please explain it in the limitation section. There might be selection biases, so the results should be interpreted with caution.